Crispr Therapeutics Ag

Demetrios Kalaitzidis

Jonathan Alexander Terrett

Lawrence Klein

Mary-Lee Dequeant

Mohammed Ghonime

Mary-Lee Dequéant

Zinkal Samir Padalia

Ewelina Morawa

Tony Ho

Mark Benton

Hanspeter Waldner

A T cell bank comprising genetically engineered T cells having one or more of the following features as compared to the non-engineered T cell counterparts: (a) enhanced expansion capacity in culture, (b) enhanced proliferation capacity, (c) reduced apoptosis, and (d) enhanced activation frequencies. Such genetically engineered T cells may comprise (i) a mutated gene involved in cell self-renewal; (ii) a disrupted gene involved in apoptosis; (iii) a disrupted gene involved in regulation of T cell exhaustion; or (iv) a combination of any one of (i)-(iii).

Genetically engineered T cells having improved persistence in culture

Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer.

Methods and compositions for treating cancer

A population of genetically engineered T cells, comprising a disrupted Reg1 gene and/or a disrupted TGFBRII gene. Such genetically engineered T cells may comprise further genetic modifications, for example, a disrupted CD70 gene. The population of genetically engineered T cells exhibit one or more of (a) improved cell growth activity; (b) enhanced persistence; and (c) reduced T cell exhaustion, (d) enhanced cytotoxicity activity, (e) resistant to inhibitory effects induced by TGF-b, and (f) resistant to inhibitory effects by fibroblasts and/or inhibitory factors secreted thereby, as compared to non-engineered T cell counterparts.

Genetically engineered T cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistence

Genetically engineered T cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistence

Genetically engineered t cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistence

Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.

Materials and methods for engineering cells and uses thereof in immuno-oncology

Genetically engineered t cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistence

A population of genetically engineered immune cells (e.g., T cells), which express a chimeric antigen receptor (CAR) specific to CD19 and contain a disrupted TRAC gene, a disrupted B2M gene, or both, for use in treating a B cell malignancy.

Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19

Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer. The methods and compositions involve genetically engineered immune cells (e.g., T cells), in which the endogenous CD70 gene is disrupted by genetic editing, for example, the CRISPR/Cas9 gene editing technology.

Growing community of inventors

Cambridge, MA, United States of America

Demetrios Kalaitzidis